当前位置: 首页 >> 检索结果
21. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study.
作者: Daniel J Weiss.;Paulina A Dzianach.;Adam Saddler.;Jailos Lubinda.;Annie Browne.;Michael McPhail.;Susan F Rumisha.;Francesca Sanna.;Yalemzewod Gelaw.;Juniper B Kiss.;Sarah Hafsia.;Rubini Jayaseelen.;Hunter S Baggen.;Punam Amratia.;Amelia Bertozzi-Villa.;Olivia Nesbit.;Joanna Whisnant.;Katherine E Battle.;Michele Nguyen.;Kefyalew Addis Alene.;Ewan Cameron.;Melissa A Penny.;Samir Bhatt.;David L Smith.;Tasmin L Symons.;Jonathan F Mosser.;Christopher J L Murray.;Simon I Hay.;Peter W Gething.
来源: Lancet. 2025年405卷10483期979-990页
Malaria remains a leading cause of illness and death globally, with countries in sub-Saharan Africa bearing a disproportionate burden. Global high-resolution maps of malaria prevalence, incidence, and mortality are crucial for tracking spatially heterogeneous progress against the disease and to inform strategic malaria control efforts. We present the latest such maps, the first since 2019, which cover the years 2000-22. The maps are accompanied by administrative-level summaries and include estimated COVID-19 pandemic-related impacts on malaria burden.
22. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
Overweight and obesity is a global epidemic. Forecasting future trajectories of the epidemic is crucial for providing an evidence base for policy change. In this study, we examine the historical trends of the global, regional, and national prevalence of adult overweight and obesity from 1990 to 2021 and forecast the future trajectories to 2050.
23. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
Despite the well documented consequences of obesity during childhood and adolescence and future risks of excess body mass on non-communicable diseases in adulthood, coordinated global action on excess body mass in early life is still insufficient. Inconsistent measurement and reporting are a barrier to specific targets, resource allocation, and interventions. In this Article we report current estimates of overweight and obesity across childhood and adolescence, progress over time, and forecasts to inform specific actions.
24. Trends in the global, regional, and national burden of oral conditions from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021.
The WHO Global Oral Health Action Plan has set an overarching global target of achieving a 10% reduction in the prevalence of oral conditions by 2030. Robust and up-to-date information on the global burden of oral conditions is paramount to monitor progress towards this target. The aim of this systematic data analysis was to produce global, WHO region, and country-level estimates of the prevalence of, and disability-adjusted life-years (DALYs) attributed to, untreated caries, severe periodontitis, edentulism, other oral disorders, lip and oral cavity cancer, and orofacial clefts from 1990 to 2021.
25. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.
作者: Francis Couturaud.;Jeannot Schmidt.;Olivier Sanchez.;Alice Ballerie.;Marie-Antoinette Sevestre.;Nicolas Meneveau.;Laurent Bertoletti.;Jérôme Connault.;Ygal Benhamou.;Joël Constans.;Thomas Quemeneur.;François-Xavier Lapébie.;Gilles Pernod.;Gaël Picart.;Antoine Elias.;Caroline Doutrelon.;Claire Neveux.;Lina Khider.;Pierre-Marie Roy.;Stéphane Zuily.;Nicolas Falvo.;Philippe Lacroix.;Joseph Emmerich.;Isabelle Mahé.;Julien Boileau.;Azzedine Yaici.;Sylvain Le Jeune.;Dominique Stéphan.;Pierre Plissonneau-Duquene.;Valérie Ray.;Marc Danguy des Déserts.;Rafik Belhadj-Chaidi.;Bouchra Lamia.;Yves Gruel.;Emilie Presles.;Philippe Girard.;Cécile Tromeur.;Farès Moustafa.;Vincent Rothstein.;Karine Lacut.;Solen Melac.;Sophie Barillot.;Patrick Mismetti.;Silvy Laporte.;Dominique Mottier.;Guy Meyer.;Christophe Leroyer.; .
来源: Lancet. 2025年405卷10480期725-735页
In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.
26. The African Critical Illness Outcomes Study (ACIOS): a point prevalence study of critical illness in 22 nations in Africa.
Critical illness represents a major global health-care burden and critical care is an essential component of hospital care. There are few data describing the prevalence, treatment, and outcomes of critically ill patients in African hospitals.
28. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
作者: Roland Veltkamp.;Eleni Korompoki.;Kirsten H Harvey.;Emily R Harvey.;Cornelia Fießler.;Uwe Malzahn.;Viktoria Rücker.;Joan Montaner.;Valeria Caso.;Igor Sibon.;Peter Ringleb.;Omid Halse.;Klemens Hügen.;Sabine Ullmann.;Carolin Schuhmann.;Gabriele Putz Todd.;Kirsten Haas.;Elena Palà.;Stéphanie Debette.;Morgane Lachaize.;Tim D'Aoust.;Christian Enzinger.;Stefan Ropele.;Simon Fandler-Höfler.;Melanie Haidegger.;Yanzhong Wang.;Hatem A Wafa.;Virginia Cancelloni.;Maria Giulia Mosconi.;Gregory Y H Lip.;Deirdre A Lane.;Walter E Haefeli.;Kathrin I Foerster.;Viktoria S Wurmbach.;Peter Brønnum Nielsen.;Karim Hajjar.;Patrick Müller.;Sven Poli.;Jan Purrucker.;Mona Laible.;Lucio D'Anna.;Yolanda Silva.;Reyes de Torres Chacon.;Patricia Martínez-Sánchez.;Marion Boulanger.;Bo Norrving.;Guillaume Paré.;Rolf Wachter.;George Ntaios.;Charles D A Wolfe.;Peter U Heuschmann.; .
来源: Lancet. 2025年405卷10482期927-936页
Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but the benefits and risks in survivors of intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage.
29. A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
作者: John M Dennis.;Katherine G Young.;Pedro Cardoso.;Laura M Güdemann.;Andrew P McGovern.;Andrew Farmer.;Rury R Holman.;Naveed Sattar.;Trevelyan J McKinley.;Ewan R Pearson.;Angus G Jones.;Beverley M Shields.;Andrew T Hattersley.; .
来源: Lancet. 2025年405卷10480期701-714页
Data to support individualised choice of optimal glucose-lowering therapy are scarce for people with type 2 diabetes. We aimed to establish whether routinely available clinical features can be used to predict the relative glycaemic effectiveness of five glucose-lowering drug classes.
30. 20th anniversary of the WHO Framework Convention on Tobacco Control coming into force: time for a step change in ambition.
作者: Anna B Gilmore.;Cynthia Callard.;Deborah Sy.;Blanca A Llorente.;Upendra Bhojani.;Catherine O Egbe.;Stella Aguinaga Bialous.
来源: Lancet. 2025年405卷10480期677-681页 31. Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study.
作者: Michel Michaelides.;Yannik Laich.;Sui Chien Wong.;Ngozi Oluonye.;Serena Zaman.;Neruban Kumaran.;Angelos Kalitzeos.;Harry Petrushkin.;Michalis Georgiou.;Vijay Tailor.;Marc Pabst.;Kim Staeubli.;Roni O Maimon-Mor.;Peter R Jones.;Steven H Scholte.;Anastasios Georgiadis.;Jacqueline van der Spuy.;Stuart Naylor.;Alexandria Forbes.;Tessa M Dekker.;Eugene R Arulmuthu.;Alexander J Smith.;Robin R Ali.;James W B Bainbridge.
来源: Lancet. 2025年405卷10479期648-657页
Retinal dystrophy caused by genetic deficiency of AIPL1 causes severe and rapidly progressive impairment of sight from birth. We sought to evaluate whether early intervention by gene supplementation therapy was safe and could improve outcomes in children with this condition.
34. Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial.
作者: Giulia Argentesi.;Xilin Wu.;Alexander Ney.;Emily Goodchild.;Kate Laycock.;Yun-Ni Lee.;Russell Senanayake.;James MacFarlane.;Elisabeth Ng.;Jessica Kearney.;Sam O'Toole.;Jackie Salsbury.;Nick Carroll.;Daniel Gillett.;John A Tadross.;Alison Marker.;Edmund M Godfrey.;George Goodchild.;Jonathan P Bestwick.;Mark Gurnell.;Heok Cheow.;Stephen P Pereira.;William M Drake.;Morris J Brown.; .
来源: Lancet. 2025年405卷10479期637-647页
Unilateral aldosterone-producing adrenal adenomas (APAs) are the potentially curable cause of 5% of all cases of hypertension. Their localisation (via adrenal vein sampling [AVS]) and removal (by laparoscopic adrenalectomy) require invasive procedures that are unattractive to patients. Molecular imaging-located, endoscopic ultrasound-guided trans-gastric radiofrequency ablation (EUS-RFA) is a potential novel, minimally invasive alternative to AVS and total adrenalectomy for the treatment of APAs in the left adrenal gland, which is very close to the stomach. We aimed to determine whether EUS-RFA can safely target a heterogeneous set of such tumours without damaging the rest of the adrenal gland or adjacent organs.
37. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
作者: Nirosen Vijiaratnam.;Christine Girges.;Grace Auld.;Rachel McComish.;Alexa King.;Simon S Skene.;Steve Hibbert.;Alan Wong.;Sabina Melander.;Rachel Gibson.;Helen Matthews.;John Dickson.;Camille Carroll.;Abigail Patrick.;Jemma Inches.;Monty Silverdale.;Bethan Blackledge.;Jessica Whiston.;Michele Hu.;Jessica Welch.;Gordon Duncan.;Katie Power.;Sarah Gallen.;Jacqueline Kerr.;K Ray Chaudhuri.;Lucia Batzu.;Silvia Rota.;Edwin Jabbari.;Huw Morris.;Patricia Limousin.;Nigel Greig.;Yazhou Li.;Vincenzo Libri.;Sonia Gandhi.;Dilan Athauda.;Kashfia Chowdhury.;Tom Foltynie.
来源: Lancet. 2025年405卷10479期627-636页
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.
38. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
作者: Janet A Dunn.;Peter Donnelly.;Nada Elbeltagi.;Andrea Marshall.;Amy Hopkins.;Alastair M Thompson.;Riccardo Audisio.;Sarah E Pinder.;David A Cameron.;Sue Hartup.;Lesley Turner.;Annie Young.;Helen Higgins.;Eila K Watson.;Sophie Gasson.;Peter J Barrett-Lee.;Claire Hulme.;Bethany Shinkins.;Peter S Hall.;Andrew Evans.
来源: Lancet. 2025年405卷10476期396-407页
The frequency of mammographic surveillance for women after diagnosis of breast cancer varies globally. The aim of this study was to evaluate whether less than annual mammography was non-inferior in terms of breast cancer-specific survival in women aged 50 years or older.
40. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
作者: Michelle C Williams.;Ryan Wereski.;Christopher Tuck.;Philip D Adamson.;Anoop S V Shah.;Edwin J R van Beek.;Giles Roditi.;Colin Berry.;Nicholas Boon.;Marcus Flather.;Steff Lewis.;John Norrie.;Adam D Timmis.;Nicholas L Mills.;Marc R Dweck.;David E Newby.; .
来源: Lancet. 2025年405卷10475期329-337页
The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in management and outcomes.
|